Ivermectin moxidectin for treating infection: a systematic review

dc.contributor.authorHenriquez-Camacho, Cesar
dc.contributor.authorPérez-Molina, Jose A
dc.contributor.authorBuonfrate, Dora
dc.contributor.authorRodari, Paola
dc.contributor.authorGotuzzo, Eduardo
dc.contributor.authorLuengo, Benilde
dc.contributor.authorPlana, María Nieves
dc.date.accessioned2025-07-18T08:41:56Z
dc.date.available2025-07-18T08:41:56Z
dc.date.issued2024-11
dc.description.abstractThe aim was to assess the efficacy of ivermectin moxidectin for treating infection. Ovid MEDLINE, Embase and Web of Science databases were searched for studies comparing ivermectin and moxidectin from inception to February 2024. The outcomes: elimination of infection or parasitological cure, mortality and serious adverse events. We calculated odds ratios (ORs) with 95% confidence intervals (CIs) for dichotomous data. Heterogeneity was assessed using Chi2 test for statistical heterogeneity and results of the statistic. Two trials met the inclusion criteria that included 821 adult participants. Both studies were conducted in southeast Asia (Cambodia and Laos). Neither trial included immunocompromised patients. The mean age of the participants ranged from 40 to 45 years old, with a similar distribution of males and females. For all participants, infection was confirmed by Baermann method. The evidence was moderate for parasitological cure rate. Certainty was downgraded by 1 level because of imprecision. Moxidectin was not inferior to ivermectin: OR 0.67, 95% CI 0.36–1.25 ( = 0.21), = 0%, 821 participants. No deaths were reported in either trial. One trial reported mild adverse events. In total, 153/726 (21%) participants had an adverse event. The most reported symptoms were abdominal pain and headache. There is evidence for moderate quality that moxidectin is non-inferior to, and as safe as ivermectin; however, more high-quality and well-designed trials are needed. For patients with some underlying immunosuppressive disorder, or in patients who are very young or very old, current data are insufficient to be recommended.
dc.identifier.citationHenriquez-Camacho C, Pérez-Molina JA, Buonfrate D, Rodari P, Gotuzzo E, Luengo B, Plana MN. Ivermectin vs moxidectin for treating Strongyloides stercoralis infection: a systematic review. Parasitology. 2024 Nov;151(13):1466-1472.
dc.identifier.doi10.1017/S0031182024001215
dc.identifier.other39819639
dc.identifier.urihttps://hdl.handle.net/10115/93417
dc.language.isoen
dc.publisherCambridge University Press
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectStrongyloides stercoralis
dc.subjectivermectin
dc.subjectmoxidectin
dc.subjectparasitological cure
dc.titleIvermectin moxidectin for treating infection: a systematic review
dc.typeArticle

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
parasitology.pdf
Tamaño:
717.26 KB
Formato:
Adobe Portable Document Format